Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 12/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376986 | 0.86 | METAP2 (0.50) | METAP2LMNAMEN1KMT2A | |
| SCHEMBL6249119 | 0.85 | MEN1 (0.52) | METAP2PKMLMNAMEN1KMT2A | |
| SCHEMBL5376455 | 0.83 | METAP2 (0.46) | METAP2PKMMEN1KMT2A | |
| SCHEMBL7083896 | 0.83 | METAP2 (0.43) | METAP2ABCB1ABCC1ABCG2MEN1 | |
| SCHEMBL5373556 | 0.83 | METAP2 (0.66) | METAP2LMNA | |
| SCHEMBL5377242 | 0.82 | METAP2 (0.65) | METAP2MEN1KMT2A | |
| SCHEMBL5376830 | 0.82 | METAP2 (0.67) | METAP2MEN1KMT2ACHEK1 | |
| SCHEMBL5379154 | 0.82 | METAP2 (0.50) | METAP2LMNAMEN1KMT2A | |
| SCHEMBL5372069 | 0.82 | METAP2 (0.56) | METAP2 | |
| SCHEMBL5385753 | 0.82 | USP2 (0.47) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | METAP2 1/4885PKM 2021/4885ABCB1 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.